Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection.
Journal: Frontiers in oncology
Published: February 08, 2024
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 19, 2023
MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas.
Journal: Oncotarget
Published: August 01, 2018
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Journal: The Journal of investigative dermatology
Published: November 10, 2015
Showing 1-5 of 5
Last Updated: 09/26/2026